Aging
Conditions
Interventions
The treatment will be administered orally, according to the following outline: Study Group: 1 pill of Vimang®, 300 mg every 8 hours, one hour before the ingestion of foods, during 6 months to reach a
Antioxidants
Tablets
Administration, Oral
Placebos
Sponsors
Center of Pharmaceutical Chemistry
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Persons with 60 year-old or more 2. Written acceptance and voluntary of participating in the clinical trial 3. Good psychological conditions. 4. People that are internal in the Home. 5. Both sexes.
Exclusion criteria
Exclusion criteria: 1. Infection systemic chronicle. 2. Treatment with anti oxidanting in the last month. 3. Current Hyperbaric Oxygenation or in one period of up to 15 days before the moment of their inclusion. 4. Immunosupresive Therapy or steroids therapy in the moment of their inclusion or in the last 3 months. 5. Renal chronicle or failure or hepatical demonstrated clinically. 6. People with cognitive damage. 7. People with dysphagia. 8. People in period of convalescence (up to two weeks) of a sharp infectious illness that could alter the immune answer. 9. Hypersensibility reaction to the components of the formulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti oxidating total (AOT). This variable will be measured to the beginning, 3 months of initiate the treatment and to the 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Potential peroxidation, reduced, total and oxidated Glutation. Oxidated proteins. Lipid Lipoperoxidation . Catalasa. Dismutasa superoxide, Glutation S - transferasa. Glutation reductasa, Total Hydroperoxides, indicators of quality of life, Filtered glomerular. These variables will be measured to the beginning, 3 months of initiate the treatment and to the 6 months. | — |
Countries
Cuba
Contacts
Public ContactAnnia Riaño-Montalvo
Center of Pharmaceutical Chemistry
Outcome results
None listed